Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and Deoxyribonuclease (human clone protein moiety); Dornasa alfa. Date of last search for all years available: 20 May Using the option ‘ Advanced search’, the following search terms were entered into the following fields. El impacto de primer año de tratamiento con dornasa alfa en los parámetros clínicos de pacientes con fibrosis quística: resultado de estudio brasileño.

Author: Nilkis Metaxe
Country: Bangladesh
Language: English (Spanish)
Genre: Technology
Published (Last): 17 September 2007
Pages: 390
PDF File Size: 13.50 Mb
ePub File Size: 1.63 Mb
ISBN: 824-9-94610-524-7
Downloads: 56473
Price: Free* [*Free Regsitration Required]
Uploader: Zulukinos

Dornase alfa is an orphan drug. Three age groups were assessed: Rajan S, Saiman L. The afa of dornase alfa in the treatment of cystic fibrosis. The lack of a control group not treated with dornase alfa and the heterogeneity of some clinical procedures adopted in the participating centers are also limitations of this study.

Clinical use of dornase alfa, a recombinant human deoxyribonuclease I that reduces the viscosity of CF sputum through the dornssa of DNA accumulated in secretions 11has demonstrated significant efficacy in CF, as it reduces respiratory exacerbations and improves lung function, regardless of patients age or disease stage 512 Use the missed dose as soon as you remember it.

Data were summarized using descriptive statistics suitable for each variable. Our aim was to investigate whether the improvements observed in patients’ QoL 14 would dornasw reflect benefits in clinical status.

Dornase Alfa

Pulmonary complications of cystic fibrosis. Continue to use dornase alfa even if you feel well. In addition, treatment with dornase alfa for 6 and 12 months was not alfq with significant changes in pulmonary function parameters, with the exception of Shwachman-Kulczychi score that showed a significant improvement after 6 months of dornase alfa Table 3.


Regarding the age group years, pulmonary function parameters are summarized in Table 2. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 years old.

Clinical outcomes and data on concomitant treatments, medication use, and routine therapies were based on data recorded. Tabela 3 Visitas ao ambulatorio e as emergencias, hospitalizacoes e parametros de funcao pulmonar nos ultimos seis meses antes do inicio do estudo, aos seis e aos 12 meses apos o inicio de dornase alfa em pacientes com idade. Dornase alfa may be considered as a therapeutic option in non-cystic fibrosis pediatric patients with pulmonary atelectasis, who require treatment intervention when conventional therapy is unsuccessful.

Drug created on June 13, Copyright and License information Disclaimer. Clarke SA, Eiser C. In view of the current recommendations regarding the use of dornase alfa, it was decided not to have a control group, as the use of placebo or another mucolytic drug would alfz ethically questionable 5 Frequency and percentages were used for categorical variables and for ordinal numerical variables.

In our study, treatment with dornase alfa did not promote significant changes in a mean FEV 1 after one year of use, as compared to baseline, in all age groups. Dornase alfa Xlfa 1. While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids.

The aim of this publication is to present additional information about the clinical profile of CF Brazilian patients after starting dornase alfa chronic use and to analyze their clinical parameters and patterns of care. A significant reduction in the number of emergency room visits due to acute exacerbations was coincident with improvement in the QoL Respiratory Domain of previous paper Cystic fibrosis CF is a disease dorjasa by the retention of viscous purulent secretions in the airways.


In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume.

Patients were followed in five outpatient visits: Open in a separate window. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. The main method of CF diagnosis was based on two sweat tests associated or not to genetic studies. This article has been cited by other articles in PMC.


Monaldi Arch Chest Dis. Cystic Fibrosis Foundation [cited Sep 20]; [homepage on the Internet].

The importance of this publication resides on the fact that it was mostly prospective, following a standardized documentation used in all 16 CF centers, with a significant number of patients. Data on patients aged from 6 to 11 years are summarized in Table1. A two-year randomized, afa trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. It usually is taken one or two times a day.